ESTRO 2022 - Abstract Book

S230

Abstract book

ESTRO 2022

Conclusion The HEI index proved to be a prognosticator in ASCC patients treated with CHT-RT. Model discrimination in the external validation cohort was acceptable.

Proffered Papers: Physics, gynaecology, prostate

OC-0273 Brachytherapy versus advanced external beam radiotherapy in terms of dosimetry

T. Major 1,2 , G. Fröhlich 3,4 , P. Ágoston 1,2 , C. Polgár 1,2 , Z. Takácsi-Nagy 1,2

1 National Institute of Oncology, Centre of Radiotherapy, Budapest, Hungary; 2 Semmelweis University, Department of Oncology, Budapest, Hungary; 3 National Insitute of Oncology, Centre of Radiotherapy, Budapest, Hungary; 4 Eötvös Loránd University, Faculty of Science, Budapest, Hungary Purpose or Objective Recently, the use of brachytherapy (BT) has been declining worldwide for various reasons. The aim of this presentation is to provide a dosimetric overview of the role of brachytherapy in the treatment of different anatomical sites of cancer patients in the era of advanced external beam radiotherapy (EBRT). Materials and Methods A systematic literature search was conducted and publications on dosimetrical comparison between BT and EBRT were collected. The studies were categorized and evaluated according to the tumour location. In addition, treatment plans with identical CT images and contours were created for BT, IMRT/VMAT and Cyberknife (CK) treatments for patients with breast,